Royal Bank of Canada
DNTH icon

Royal Bank of Canada’s Dianthus Therapeutics DNTH Stock Holding History

Royal Bank of Canada’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Sell
4,331
-14,733
-77% -$1.29M ﹤0.01% 4495
2026
Q1 		$1.6M Buy
19,064
+17,052
+848% +$987K ﹤0.01% 3263
2025
Q4 		$82K Buy
2,012
+542
+37% +$21K ﹤0.01% 5301
2025
Q3 		$59K Sell
1,470
-2,591
-64% -$66.2K ﹤0.01% 5748
2025
Q2 		$76K Sell
4,061
-723
-15% -$13.6K ﹤0.01% 5742
2025
Q1 		$86K Sell
4,784
-5,252
-52% -$116K ﹤0.01% 5307
2024
Q4 		$220K Sell
10,036
-18,895
-65% -$486K ﹤0.01% 4739
2024
Q3 		$792K Buy
28,931
+26,602
+1,142% +$741K ﹤0.01% 3728
2024
Q2 		$60K Buy
2,329
+2,248
+2,775% +$54K ﹤0.01% 5559
2024
Q1 		$2K Sell
81
-254
-76% -$5.52K ﹤0.01% 6662
2023
Q4 		$4K Sell
335
-4
-1% -$44 ﹤0.01% 6677
2023
Q3 		$4K Sell
339
-26
-7% -$328 ﹤0.01% 6650
2023
Q2 		$4K Buy
365
+29
+9% +$330 ﹤0.01% 6724
2023
Q1 		$4K Hold
336
– – ﹤0.01% 6616
2022
Q4 		$3K Sell
336
-1
-0.3% -$18 ﹤0.01% 6844
2022
Q3 		$8K Buy
337
+67
+25% +$1.83K ﹤0.01% 6524
2022
Q2 		$5K Sell
270
-99
-27% -$2.45K ﹤0.01% 6636
2022
Q1 		$17K Sell
369
-317
-46% -$17.3K ﹤0.01% 6682
2021
Q4 		$48K Buy
686
+269
+65% +$27K ﹤0.01% 6393
2021
Q3 		$49K Buy
417
+28
+7% +$3.26K ﹤0.01% 6172
2021
Q2 		$61K Buy
389
+85
+28% +$15.6K ﹤0.01% 5902
2021
Q1 		$57K Buy
304
+119
+64% +$20K ﹤0.01% 5797
2020
Q4 		$24K Buy
185
+60
+48% +$6.8K ﹤0.01% 5977
2020
Q3 		$14K Hold
125
– – ﹤0.01% 5817
2020
Q2 		$15K Sell
125
-4
-3% -$564 ﹤0.01% 5685
2020
Q1 		$13K Sell
129
-119
-48% -$22.1K ﹤0.01% 5722
2019
Q4 		$60K Buy
248
+123
+98% +$23K ﹤0.01% 5360
2019
Q3 		$21K Buy
125
+44
+54% +$8.36K ﹤0.01% 5484
2019
Q2 		$19K Hold
81
– – ﹤0.01% 5737
2019
Q1 		$21K Buy
+81
New +$14K ﹤0.01% 5624
2018
Q4 		– Sell
-14
Closed -$3K – 6823
2018
Q3 		$3K Buy
+14
New +$2.95K ﹤0.01% 6409

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Royal Bank of Canada's DNTH Position: Q2 2026 in Review

Royal Bank of Canada reduced its Dianthus Therapeutics (DNTH) stake by 77% in Q2 2026, selling an estimated $1.29M and leaving 4,331 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #4495.

Royal Bank of Canada first reported a position in DNTH in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.6M in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Royal Bank of Canada held 4,331 shares of Dianthus Therapeutics worth $423K as of Q2 2026.
  • Royal Bank of Canada sold 14,733 Dianthus Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Dianthus Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4495 holding.
  • Royal Bank of Canada first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Royal Bank of Canada's Dianthus Therapeutics position peaked at $1.6M in Q1 2026.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.